Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience.

e11509 Background: Trastuzumab (T) is associated with significant outcome improvement in HER2 positive early stage breast cancer (BC). Adjuvant T was registered in Italy in 2005 for clinical practice. INT-HER study, single institution experience, report the long term results in unselected HER2-positive BC patients (pts). Methods: We analyze 296 pts with HER2+ve BC (defined as IHC 3+ or HER2 amplification) consecutively treated at the Fondazione IRCCS Istituto Nazionale Tumori from October 2005 to February 2012. T was administered for 1 year (q 3wks) as part of an integrated plan of loco-regional treatment, neo-adjuvant or adjuvant chemotherapy (CT) and hormone-therapy when indicated according to menopausal status. This retrospective study was approved by the Ethics Committee of our institution. Results: The median age at the diagnosis was 51 years (range 26-79). CT included anthracycline (A) and in 71% of pts A plus taxane. More then half of pts had pT1, 47% had pN0, 32.5% pN1-3 and 20.5% pN>4.T and N wer...